Arcus Biosciences Inc logo

RCUS - Arcus Biosciences Inc Share Price

$38.14 1.1  2.9%

Last Trade - 7:11pm

Mid Cap
Market Cap £1.75bn
Enterprise Value £1.18bn
Revenue £56.6m
Position in Universe 1953rd / 6626
Unlock RCUS Revenue
Relative Strength (%)
1m +9.68%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -7.40%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 1.41 8.35 15.0 59.1 83.6
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ArcusBiosciences Inc revenues increased from $5.3M to $68M. Netloss increased 4% to $71M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development - Balancing val increase of 88% to$103.5M (expense), General and administrative - Balancing vincrease of 55% to $22.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RCUS
Graphical History


RCUS Revenue Unlock RCUS Revenue

Net Income

RCUS Net Income Unlock RCUS Revenue

Normalised EPS

RCUS Normalised EPS Unlock RCUS Revenue

PE Ratio Range

RCUS PE Ratio Range Unlock RCUS Revenue

Dividend Yield Range

RCUS Dividend Yield Range Unlock RCUS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RCUS EPS Forecasts Unlock RCUS Revenue
Profile Summary

Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated April 30, 2015
Public Since March 15, 2018
No. of Shareholders: 115
No. of Employees: 139
Sector Healthcare
Industry Pharmaceuticals
Exchange New York Stock Exchange
Shares in Issue 64,923,304
Free Float (0.0%)
Eligible for
RCUS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RCUS
Upcoming Events for RCUS
Wednesday 3rd March, 2021 Estimate
Q4 2020 Arcus Biosciences Inc Earnings Release
Monday 3rd May, 2021 Estimate
Q1 2021 Arcus Biosciences Inc Earnings Release
Frequently Asked Questions for Arcus Biosciences Inc
What is the Arcus Biosciences Inc share price?

As of 7:11pm, shares in Arcus Biosciences Inc are trading at $38.14, giving the company a market capitalisation of £1.75bn. This share price information is delayed by 15 minutes.

How has the Arcus Biosciences Inc share price performed this year?

Shares in Arcus Biosciences Inc are currently trading at $38.14 and the price has moved by 0.272k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arcus Biosciences Inc price has moved by 0.221k% over the past year.

What are the analyst and broker recommendations for Arcus Biosciences Inc?

Of the analysts with advisory recommendations for Arcus Biosciences Inc, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arcus Biosciences Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Arcus Biosciences Inc next release its financial results?

Arcus Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Arcus Biosciences Inc dividend yield?

Arcus Biosciences Inc does not currently pay a dividend.

Does Arcus Biosciences Inc pay a dividend?

Arcus Biosciences Inc does not currently pay a dividend.

When does Arcus Biosciences Inc next pay dividends?

Arcus Biosciences Inc does not currently pay a dividend.

How do I buy Arcus Biosciences Inc shares?

To buy shares in Arcus Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arcus Biosciences Inc?

Shares in Arcus Biosciences Inc are currently trading at $38.14, giving the company a market capitalisation of £1.75bn.

Where are Arcus Biosciences Inc shares listed? Where are Arcus Biosciences Inc shares listed?

Here are the trading details for Arcus Biosciences Inc:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: RCUS
What kind of share is Arcus Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Arcus Biosciences Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arcus Biosciences Inc share price forecast 2021?

Shares in Arcus Biosciences Inc are currently priced at $38.14. At that level they are trading at 3.16% discount to the analyst consensus target price of 0.00.

Analysts covering Arcus Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.742 for the next financial year.

How can I tell whether the Arcus Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcus Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been 40.67%. At the current price of $38.14, shares in Arcus Biosciences Inc are trading at 46.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arcus Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Arcus Biosciences Inc.

Who are the key directors of Arcus Biosciences Inc?

Arcus Biosciences Inc's management team is headed by:

Terry Rosen - CHM
Juan Jaen - PRE
Jennifer Jarrett - COO
William Grossman - OTH
Yasunori Kaneko - LED
Eric Hoefer - OTH
Jason Barker - VFN
Patrick Machado - DRC
David Lacey - DRC
Robert Goeltz - CFO
Merdad Parsey - DRC
Andrew Perlman - DRC
Who are the major shareholders of Arcus Biosciences Inc?

Here are the top five shareholders of Arcus Biosciences Inc based on the size of their shareholding:

Gilead Sciences Inc Corporation
Percentage owned: 12.57% (8.16m shares)
Alphabet, Inc. Holding Company
Percentage owned: 7.78% (5.05m shares)
Rosen Terry Jay Individual Investor
Percentage owned: 6.71% (4.36m shares)
Partner Fund Management, L.L.C. Hedge Fund
Percentage owned: 5.2% (3.37m shares)
BVF Partners L.P. Hedge Fund
Percentage owned: 4.24% (2.75m shares)
Similar to RCUS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.